Actinium Pharmaceuticals(US:ATNM) Prnewswireยท2025-05-16 09:45Core Viewpoint - A class action securities lawsuit has been filed against Actinium Pharmaceuticals, alleging securities fraud that negatively impacted investors between October 31, 2022, and August 2, 2024 [1][2]. Group 1: Lawsuit Details - The complaint claims that the defendants made false statements regarding the Phase 3 Sierra trial data, which was unlikely to meet FDA guidelines for the approval of the targeted radiotherapy, Iomab-B BLA [2]. - It is alleged that additional analyses provided to the FDA, intended to show improved Overall Survival, were also unlikely to satisfy FDA requirements for Iomab-B BLA approval [2]. - The lawsuit suggests that the FDA would likely refuse to review the Iomab-B BLA or that the application, in its current form, was unlikely to be approved [2]. - Defendants' positive statements about the Company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses in Actinium during the specified timeframe have until May 27, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].